FIELD: medicine.
SUBSTANCE: invention can be applied for blocking of chronic integration diseases caused by human immunodeficiency virus (HIV), bovine leucosis virus (BLV), bovine immunodeficiency virus (BIV), mouse leucosis virus (MuLV), equine infection anemia virus (EIA) and hepatitis B virus. Effect is achieved by application of live cells of Mycoplasma arginini microbe non-pathogenic to humans, used for superinfection of T lymphocyte infected with HIV.
EFFECT: enhanced specificity and efficiency of stepwise removal of integrated DNA provirus from cell genome preserving cell vitality, despite of any virus mutations.
5 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECESSIVE DIVIDING RETROVIRAL VECTOR (VARIANTS), METHOD FOR PRODUCTION THEREOF (VARIANTS), ISOLATED AND PURIFIED NUCLEIC ACID MOLECULE | 1996 |
|
RU2270250C2 |
| AGENT FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND CYTOMEGALOVIRUS (CMV) INFECTIONS AND METHOD OF THEIR INHIBITION | 2002 |
|
RU2196602C1 |
| TEST SYSTEM FOR DETERMINATION OF INTERFERON, IL23 INTERLEUKINE AND MXA ANTI-VIRUS PROTEIN RNA | 2016 |
|
RU2627179C1 |
| METHOD FOR COMPLEX- INDIVIDUALIZED IMPACT UPON BODY AT SLOW VIRAL INFECTION AND METHOD FOR PREPARING LABORATORY ANIMAL FOR TESTING THE METHOD OF SUCH IMPACT | 2001 |
|
RU2207876C1 |
| METHOD OF INHIBITING HIV REPLICATION IN CELLS OF MAMMALS AND HUMANS | 2011 |
|
RU2593948C2 |
| COMPOSITIONS AND METHODS USED FOR ASSESSING CYTOTOXICITY OF SINGLE CELLS | 2009 |
|
RU2532228C2 |
| IMMUNOBIOLOGICAL AGENT TO ENHANCE CELLULAR RESPONSE AGAINST HEPATITIS C VIRUS | 2023 |
|
RU2811136C1 |
| METHOD FOR VIRUS CONTROLLING USING SUBSTANCE BASED ON 2,8-DITHIOXO-1H-PYRANO[2,3-d;6,5-d']DIPYRIMIDINE AND 10-AZA- ANALOGS THEREOF (VARIANTS) | 2005 |
|
RU2294367C2 |
| METHOD OF TREATING CHRONIC DISEASES OF EAR-NOSE-THROAT ORGANS WITH VIRAL, BACTERIAL, AND MIXED VIRAL-BACTERIAL ETIOLOGY IN HIV-INFECTED CHILDREN AND ADOLESCENTS | 2004 |
|
RU2305558C2 |
| METHOD FOR SIMULATING CYTOMEGALOVIRUS INFECTION IN INDIVIDUAL FOR STUDYING AND TESTING ANTIVIRAL COMPOUNDS AND TRANSPLANT FOR IMPLEMENTING IT | 2013 |
|
RU2544287C2 |
